Short-term assessment of 0.1% hydrocortisone 17-butyrate ('Locoid') in the treatment of skin disease.
An assessment was made of the local use of 0.1% hydrocortisone 17-butyrate in the treatment of 15 patients with a variety of skin conditions involving face and neck. Treatment was used on a short-term basis ranging from 3 to 22 days. There was marked clinical improvement of the lesions in 12 patients. The results of this short study are in accord with earlier published work and suggest that this new nonfluorinated steroid has promising potential.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D002087:Butyrates / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D002648:Child; D005145:Face / Q000187:drug effects; D005260:Female; D006801:Humans; D006854:Hydrocortisone; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009333:Neck / Q000187:drug effects; D011565:Psoriasis / Q000188:drug therapy / Q000473:pathology; D012871:Skin Diseases / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D002087:Butyrates; D006854:Hydrocortisone